Treatment of Diffuse Large B Cell Lymphoma

다국어 초록 (Multilingual Abstract)

Diffuse large B cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma in all countries and all age groups. DLBCL is potentially curable, and the outcome of patients with DLBCL has completely changed with the introduction of therapy involving the monoclonal antibody rituximab in combination with chemotherapy. Nonetheless, relapse is detected after treatment with rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisolone in approximately 30% of patients. It has recently become clear that DLBCL represents a heterogeneous admixture of quite different entities. Gene expression profiling has uncovered DLBCL subtypes that have distinct clinical behaviors and prognoses; however, incorporation of this information into treatment algorithms awaits further investigation. Future approaches to DLBCL treatment will use this new genetic information to identify potential biomarkers for prognosis and targets for treatment.

참고문헌 (Reference)

1 Swerdlow SH, "WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed" International Agency for Research on Cancer 2008

2 Olivieri A, "Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin’s lymphoma: long-term results by the NHLCSG" 16 : 1941-1948, 2005

3 Canales MA, "Up-front treatment of diffuse large-b cell lymphoma (DLBCL) in elderly patients with rituximab in combination with CHOP-like chemotherapy: a multicenter study on the current clinical management" 106 : 4778-, 2005

4 Pfreundschuh M, "Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL" 104 : 626-633, 2004

5 Pfreundschuh M, "Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL" 104 : 634-641, 2004

6 Wiestner A, "Towards molecular diagnosis and targeted therapy of lymphoid malignancies" 40 : 296-307, 2003

7 Rosenwald A, "The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma" 346 : 1937-1947, 2002

8 Sehn LH, "The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP" 109 : 1857-1861, 2007

9 Strauss SJ, "The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines" 67 : 2783-2790, 2007

10 Phan RT, "The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells" 432 : 635-639, 2004

11 Jaffe ES, "The 2008 WHO classification of lymphomas: implications for clinical practice and translational research" 2009 : 523-531, 2009

12 Pfreundschuh M, "Six versus eight cycles of biweekly CHOP-14 with or without R in elderly patients (pts) with aggressive CD20+ B-cell lymphomas: Seven-year FU of the RICOVER-60 trial of the DSHNHL" 29 (29): 8029-, 2011

13 Pfreundschuh M, "Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)" 9 : 105-116, 2008

14 Gisselbrecht C, "Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era" 28 : 4184-4190, 2010

15 Habermann TM, "Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma" 24 : 3121-3127, 2006

16 Saito B, "Rituximab with chemotherapy improves survival of non-germinal center type untreated diffuse large B-cell lymphoma" 21 : 2563-2566, 2007

17 Mounier N, "Rituximab plus CHOP (R-CHOP) overcomes bcl-2: associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)" 101 : 4279-4284, 2003

18 Vellenga E, "Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial" 111 : 537-543, 2008

19 Kewalramani T, "Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma" 103 : 3684-3688, 2004

20 Coiffier B, "Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study" 92 : 1927-1932, 1998

21 Hernandez-Ilizaliturri FJ, "Response of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with nongerminal center B-cell phenotype to lenalidomide (L) alone or in combination with rituximab (R)" 28 (28): 8038-, 2010

22 Wilson WH, "Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin’s lymphomas" 89 : 601-609, 1997

23 Gisselbrecht C, "R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study" 27 (27): 8509-, 2009

24 Martin A, "R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study" 93 : 1829-1836, 2008

25 Delarue R, "R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma: results of the interim analysis of the LNH03-6B GELA study" 114 : 406-, 2009

26 Winter JN, "Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study" 107 : 4207-4213, 2006

27 Lee NR, "Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis" 49 : 247-256, 2008

28 Nyman H, "Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy" 109 : 4930-4935, 2007

29 Lossos IS, "Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes" 350 : 1828-1837, 2004

30 Wilson WH, "Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers" 26 : 2717-2724, 2008

31 Dunleavy K, "Phase I/II study of bortezomib alone and bortezomib with dose-adjusted EPOCH chemotherapy in relapsed or refractory aggressive B-cell lymphoma" 104 : 1385-, 2004

32 Houldsworth J, "Pathway activation in large B-cell non-Hodgkin lymphoma cell lines by doxorubicin reveals prognostic markers of in vivo response" 49 : 2170-2180, 2008

33 Pasqualucci L, "Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma" 101 : 2914-2923, 2003

34 Lenz G, "Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways" 105 : 13520-13525, 2008

35 Klimo P, "MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma" 102 : 596-602, 1985

36 Feugier P, "Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte" 23 : 4117-4126, 2005

37 Coiffier B, "Long-term results of the GELA study comparing R-CHOP and CHOP chemotherapy in older patients with diffuse large B-cell lymphoma show good survival in poor-risk patients" 25 (25): 8009-, 2007

38 Sehn LH, "Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia" 23 : 5027-5033, 2005

39 Tilly H, "Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma" 102 : 4284-4289, 2003

40 Recher C, "Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial" 378 : 1858-1867, 2011

41 van Imhoff GW, "Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin’s lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40" 23 : 3793-3801, 2005

42 Fenske TS, "Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma" 15 : 1455-1464, 2009

43 de Jong D, "Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium)" 62 : 128-138, 2009

44 Meyer PN, "Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab" 29 : 200-207, 2011

45 Shipp MA, "Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD" 104 : 757-765, 1986

46 Gutierrez-Garcia G, "Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy" 117 : 4836-4843, 2011

47 Cartron G, "From the bench to the bedside: ways to improve rituximab efficacy" 104 : 2635-2642, 2004

48 Paik JH, "Expression and prognostic implications of cell cycle regulatory molecules, p16, p21, p27, p14 and p53 in germinal centre and non-germinal centre B-like diffuse large B-cell lymphomas" 47 : 281-291, 2005

49 Browne MJ, "Excess prevalence of Pneumocystis carinii pneumonia in patients treated for lymphoma with combination chemotherapy" 104 : 338-344, 1986

50 Itoh K, "Dose-escalation study of CHOP with or without prophylactic G-CSF in aggressive non-Hodgkin’s lymphoma" 11 : 1241-1247, 2000

51 Purroy N, "Dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor risk large B-cell lymphoma. A phase 2 study conducted by the Spanish PETHEMA group" 114 : 2701-, 2009

52 Alizadeh AA, "Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling" 403 : 503-511, 2000

53 Shipp MA, "Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning" 8 : 68-74, 2002

54 Hans CP, "Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray" 103 : 275-282, 2004

55 Fisher RI, "Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma" 328 : 1002-1006, 1993

56 Aksentijevich I, "Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin’s lymphoma" 12 : 965-972, 2006

57 Horning SJ, "Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin’s lymphoma: Eastern Cooperative Oncology Group study 1484" 22 : 3032-3038, 2004

58 Pfreundschuh M, "CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group" 7 : 379-391, 2006

59 Coiffier B, "CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma" 346 : 235-242, 2002

60 Shenkier TN, "Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency" 20 : 197-204, 2002

61 Allen C, "Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer" 14 : 4175-4185, 2008

62 Ruan J, "Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma" 29 : 690-697, 2011

63 Phan J, "Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy" 28 : 4170-4176, 2010

64 Ranuncolo SM, "Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR" 8 : 705-714, 2007

65 Kurosu T, "BCL6 overexpression prevents increase in reactive oxygen species and inhibits apoptosis induced by chemotherapeutic reagents in B-cell lymphoma cells" 22 : 4459-4468, 2003

66 Bagg A, "B cells behaving badly: a better basis to behold belligerence in B-cell lymphomas" 2011 : 330-335, 2011

67 Vose JM, "Autologous transplantation for aggressive non-Hodgkin’s lymphoma: results of a randomized trial evaluating graft source and minimal residual disease" 20 : 2344-2352, 2002

68 Fu K, "Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma" 26 : 4587-4594, 2008

69 Reyes F, "ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma" 352 : 1197-1205, 2005

70 Linch DC, "A randomized British National Lymphoma Investigation trial of CHOP vs. a weekly multi-agent regimen (PACEBOM) in patients with histologically aggressive non-Hodgkin’s lymphoma" 11 (11): 87-90, 2000

71 Choi WW, "A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy" 15 : 5494-5502, 2009

72 Lazarus HM, "A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR" 16 : 35-45, 2010